419,900 Shares in Cryoport, Inc. (NASDAQ:CYRX) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. purchased a new stake in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 419,900 shares of the company’s stock, valued at approximately $3,405,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CYRX. AXA S.A. boosted its holdings in Cryoport by 274.2% during the 2nd quarter. AXA S.A. now owns 873,217 shares of the company’s stock valued at $6,034,000 after acquiring an additional 639,855 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Cryoport during the second quarter valued at approximately $774,000. Assenagon Asset Management S.A. boosted its stake in shares of Cryoport by 52.9% during the second quarter. Assenagon Asset Management S.A. now owns 1,477,693 shares of the company’s stock valued at $10,211,000 after purchasing an additional 511,064 shares during the period. SG Americas Securities LLC grew its holdings in shares of Cryoport by 278.6% in the third quarter. SG Americas Securities LLC now owns 101,359 shares of the company’s stock worth $822,000 after purchasing an additional 74,590 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Cryoport in the second quarter worth $378,000. 92.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on CYRX shares. Roth Mkm cut their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. UBS Group raised their target price on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cryoport currently has an average rating of “Moderate Buy” and an average target price of $12.50.

Cryoport Stock Up 0.8 %

Shares of NASDAQ CYRX opened at $7.33 on Monday. The firm has a fifty day simple moving average of $7.31 and a two-hundred day simple moving average of $8.18. Cryoport, Inc. has a 12 month low of $5.32 and a 12 month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $362.33 million, a PE ratio of -2.17 and a beta of 1.62.

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now directly owns 59,497 shares in the company, valued at $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock valued at $735,673 over the last three months. Corporate insiders own 10.10% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.